Listen to the latest episode of the ASBMB's science policy podcast with Public Affairs Director Benjamin Corb.
Find all of the Pipettes & Politics episodes on Soundcloud, or subscribe wherever you get your podcasts.
Remote study sections
The coronavirus pandemic has forced federal agencies to move study sections to virtual settings, allowing reviews to continue while also allowing reviewers to follow federal guidance restricting travel and personal interactions.
In an effort to measure and understand the impact that remote peer review might have on science (positive or negative) the ASBMB encourages you to take a moment and share your thoughts and experiences regarding online study sections.
ASBMB statement on FDA emergency use reauthorization of blood plasma therapy for COVID-19 patients
August 23, 2020
ASBMB rejects President Donald Trump's accusations against scientists
August 20, 2020
ASBMB Supporting the Independence of Science Sign on letter
May 20, 2020
ASBMB statement on HEROES Act
May 13, 2020
ASBMB statement on revocation of EcoHealth Alliance grant on bat–human virus transmission
April 28, 2020
ASBMB statement on U.S. Sen. Tom Cotton’s remarks on Chinese students in the U.S.
Apr 27, 2020
ASBMB statement on COVID-19 stimulus package
Mar 25, 2020
As the world awaits vaccines to bring the COVID-19 pandemic under control, UC San Francisco scientists have devised a novel approach to halting the spread of SARS-CoV-2, the virus that causes the disease.
Scientists in Germany tested the malaria drugs on various cell types and found they can block coronavirus infection in kidney cells from the African green monkey but don’t inhibit the virus in human lung cells.
In a summer dominated by COVID-19 and protests against racial injustice, there are growing demands that drugmakers and investigators ensure that vaccine trials reflect the entire community.
Our bodies have two main types of T cells. Together they can help us fend off this virus
They’re easier to manufacture than traditional vaccines, but scientifically their history is checkered
Amid a wavering federal response that has allowed staggering levels of disease to sweep the country, the All of Us program is a potential bright spot.
An infected and impatient world needs protection from Covid-19, but rushing it won't be easy. How can we speed up a complicated process?
Five months into a pandemic with arguably the world’s worst response, the United States can no longer take the easy way out and blame only politics for our downfall. We’re to blame, too.
New study finds that a coronavirus vaccine’s effectiveness may have to be higher than 70% or even 80% before Americans can safely stop relying on social distancing.
Severe scrutiny of two major papers, including one about the effectiveness of hydroxychloroquine, is part of science's normal process of self-correction, explains Mark R. O’Brian.
Labs are trying to reopen and get back to research while not spreading COVID-19. Great goal, but how do we do that?
Resources from the ASBMB
See our list of guidance and resources from the NSF, NIH, DOE and others.
A panel discussion about how scientists can use their credibility and critical thinking to cut through the noise and guide the national COVID-19 dialogue.
COVID-19 resources for librarians, campuses and health professionals
Access to coronavirus research, textbooks, text and data mining, and clinical information from Elsevier.
Sharing, discovering and citing COVID-19 data and code
A webinar from the NIH.
Open-access data and computational resources to address COVID-19
NIH curated list of links to data sources.
Virtual NIH activities for trainees outside the NIH
Resources from the NIH Office of Intramural Training & Education, including online workshops.
Daily conversations with TED talkers.
Discussions on the biomedical workforce in the time of COVID-19
A series of discussions hosted by Rescuing Biomedical Research.
JBC's coronavirus virtual issue presents a retrospective collection of content on coronavirus entry, proteases and host interactions to help researchers build more quickly toward therapeutic endpoints against SARS-CoV-2 and future strains.